Position in OCGN
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$674,329
-$120,148 QoQ
Shares Held
440,738
+0.4% QoQ
Ownership
0.130%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#3
of 35 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in OCGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Procyon Advisors, LLC holds $7,050,049 across 8 Biotechnology names. OCGN ranks #3 (9.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
22,962 | $2,602,972 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,924 | $1,452,438 | |
| 3 | OCGN |
Ocugen, Inc.
This page
|
440,738 | $674,329 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
2,055 | $649,564 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
5,606 | $487,441 | |
| 6 | INVA |
Innoviva, Inc.
|
19,097 | $433,692 | |
| 7 | REGN |
Regeneron Pharmaceuticals, Inc.
|
607 | $378,488 | |
| 8 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
11,808 | $371,125 |
All Filings in OCGN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $674,329 | 440,738 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $794,477 | 438,938 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $302,535 | 224,100 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $344,093 | 211,100 | Shares | Sole | 2025-10-28 | |
| 2025-06-30 | $194,097 | 200,100 | Shares | Sole | 2025-07-09 | |
| No filing history on record for this holder in this stock. | ||||||